



# Hemlibra in Saudi Arabia

*The SFDA named-patient coordination pathway — indicative 2026*

HEMATOLOGY · HEMOPHILIA A PROPHYLAXIS (WITH/WITHOUT INHIBITORS)

## The clinical situation

Hemlibra (emicizumab) is a bispecific antibody that bridges activated factor IX and factor X to mimic factor VIIIa cofactor function. FDA-approved for routine prophylaxis in adult and paediatric Hemophilia A patients — with or without factor VIII inhibitors. Developed by Roche/Genentech and Chugai. Delivered subcutaneously on a flexible weekly, every-2-weeks, or every-4-weeks schedule. Hemlibra has a local presence in Saudi Arabia; the named-patient pathway addresses formulary, presentation, or supply gaps for specific patients. Hemlibra is prophylaxis; acute bleeds continue to require bypassing agents or FVIII as clinically indicated.

## The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist documents diagnosis, inhibitor status, the specific regimen, dose, and paediatric or adult status.
- 2 SFDA named-patient application.** Physician or importing pharmacy files dossier: rationale, patient reference, loading and maintenance regimen, weight-based dose.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 4 Cold-chain shipment.** Temperature-controlled transport with documented chain of custody.
- 5 Arrival & administration.** Subcutaneous administration per physician protocol; many patients or caregivers self-inject at home. Ongoing re-supply aligned to weekly, every-2-weeks, or every-4-weeks schedule.

## Indicative economics

**Reference US cash-pay range:** Weight- and regimen-dependent; per-dose cost typically lower on every-4-weeks schedule (adjusted for higher unit dose). Reserve Meds issues a transparent delivered quote at intake.

## Indicative first-dose timing

**10–21 days** from a complete SFDA application to first shipment; re-supply faster once pathway established. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your haematologist and SFDA review, keyed to the Hemlibra prophylaxis rationale including inhibitor status where relevant.

**Logistics.** Cold-chain shipment with continuous temperature monitoring and importer-of-record handling. We coordinate alongside — not in competition with — MoH channels where those are working. **Concierge case lead.** Named point of contact for family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Hemlibra × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/hemlibra-saudi-arabia.html](https://reservemed.com/access-guides/hemlibra-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team